Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 13/20 | 0.62 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.54 |
| ▸ | FPR1 | P21462 | 2/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6374207 | 1.00 | FPR2 (0.62) | FPR2GPR132FPR1FOLH1MEN1 | |
| SCHEMBL16008987 | 0.92 | FPR2 (0.62) | FPR2GPR132MEN1KMT2A | |
| SCHEMBL6381444 | 0.86 | FPR2 (0.81) | FPR2FOLH1MEN1KMT2A | |
| SCHEMBL6375756 | 0.86 | FPR2 (0.81) | FPR2FOLH1MEN1KMT2A | |
| SCHEMBL6375751 | 0.86 | FPR2 (0.81) | FPR2FOLH1MEN1KMT2A | |
| SCHEMBL18191807 | 0.85 | FPR2 (0.71) | FPR2FOLH1MEN1KMT2A | |
| SCHEMBL14938094 | 0.85 | FPR2 (0.71) | FPR2FOLH1MEN1KMT2A | |
| SCHEMBL6307446 | 0.82 | GPR132 (0.54) | GPR132FOLH1 | |
| SCHEMBL29686516 | 0.82 | PKM (0.54) | FPR2MEN1KMT2ANAMPT | |
| SCHEMBL10659411 | 0.81 | GPR132 (0.72) | GPR132FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137230-A1 | Carboxamide derivatives | DORSCH DIETER (DE) | 2005-06-23 | — | — | US | disclosed |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | MERCK PATENT GMBH (DE) | 2004-02-26 | — | — | US | disclosed |
| EP-1341755-A1 | CARBOXYLIC ACID AMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOEMBOLIC DISEASES AND TUMOURS | MERCK PATENT GmbH (DE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002048099-A1 | CARBOXYLIC ACID AMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOEMBOLIC DISEASES AND TUMOURS | MERCK PATENT GMBH (DE) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137230-A1 | Carboxamide derivatives | F11, F12, F2 | FPR2 766/4885GPR132 2021/4885FPR1 113/4885 |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | CNR2, CNR1, HCAR2 | FPR2 176/4885GPR132 2409/4885FPR1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.